146 related articles for article (PubMed ID: 35285577)
1. Unraveling Hürthle cell lesions of the thyroid using molecular findings.
Wong KS
Cancer Cytopathol; 2022 Jun; 130(6):405-406. PubMed ID: 35285577
[No Abstract] [Full Text] [Related]
2. Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.
Wong KS; Jo VY; Lowe AC; Faquin WC; Renshaw AA; Shah AA; Roh MH; Stelow EB; Krane JF
Cancer Cytopathol; 2020 Jan; 128(1):68-75. PubMed ID: 31751003
[TBL] [Abstract][Full Text] [Related]
3. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
4. Hurthle cells in fine needle aspiration cytology of the thyroid: a potential diagnostic dilemma?
Wong YP; Md Isa N; Md Zin RR; Noor Akmal S
Malays J Pathol; 2015 Apr; 37(1):49-52. PubMed ID: 25890614
[TBL] [Abstract][Full Text] [Related]
5. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma.
Sponziello M; Silvestri G; Verrienti A; Perna A; Rosignolo F; Brunelli C; Pecce V; Rossi ED; Lombardi CP; Durante C; Filetti S; Fadda G
Endocrine; 2018 Nov; 62(2):492-495. PubMed ID: 29700698
[No Abstract] [Full Text] [Related]
6.
Endo M; Nabhan F; Angell TE; Harrell RM; Nasr C; Wei S; Sipos JA
Thyroid; 2020 Sep; 30(9):1390-1392. PubMed ID: 32228149
[No Abstract] [Full Text] [Related]
7. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries.
Agarwal S; Bychkov A; Jung CK; Hirokawa M; Lai CR; Hong S; Kwon HJ; Rangdaeng S; Liu Z; Su P; Kakudo K; Jain D
Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897
[TBL] [Abstract][Full Text] [Related]
8. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
Elliott DD; Pitman MB; Bloom L; Faquin WC
Cancer; 2006 Apr; 108(2):102-9. PubMed ID: 16453320
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations in Hürthle cell nodules and preoperative cancer risk.
Doerfler WR; Nikitski AV; Morariu EM; Ohori NP; Chiosea SI; Landau MS; Nikiforova MN; Nikiforov YE; Yip L; Manroa P
Endocr Relat Cancer; 2021 Apr; 28(5):301-309. PubMed ID: 33792557
[TBL] [Abstract][Full Text] [Related]
10. Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease.
Alaedeen DI; Khiyami A; McHenry CR
Surgery; 2005 Oct; 138(4):650-6; discussion 656-7. PubMed ID: 16269293
[TBL] [Abstract][Full Text] [Related]
11. Predictors of malignancy in patients with a thyroid nodule that contains Hürthle cells.
Turanli S; Pirhan Y; Ozcelik CK; Cetin A
Otolaryngol Head Neck Surg; 2011 Apr; 144(4):514-7. PubMed ID: 21493226
[TBL] [Abstract][Full Text] [Related]
12. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
[No Abstract] [Full Text] [Related]
13. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
14. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
[TBL] [Abstract][Full Text] [Related]
15. Thyroid nodules 2006: managing what has been known for over 50 years.
Garber JR
Hormones (Athens); 2006; 5(3):179-86. PubMed ID: 16950751
[No Abstract] [Full Text] [Related]
16. Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms.
McFadden DG; Sadow PM
Front Endocrinol (Lausanne); 2021; 12():696386. PubMed ID: 34177816
[TBL] [Abstract][Full Text] [Related]
17. "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms.
Kim TH; Rodriguez EF; Lim D; Moatamed NA
Diagn Cytopathol; 2023 Nov; 51(11):705-711. PubMed ID: 37533334
[TBL] [Abstract][Full Text] [Related]
18. Challenges in Cytology Specimens With Hürthle Cells.
Thodou E; Canberk S; Schmitt F
Front Endocrinol (Lausanne); 2021; 12():701877. PubMed ID: 34248855
[TBL] [Abstract][Full Text] [Related]
19. IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?
Lupo M; Guttler R; Geck Z; Tonozzi TR; Kammesheidt A; Braunstein GD
Endocr Pract; 2018 May; 24(5):453-459. PubMed ID: 29498908
[TBL] [Abstract][Full Text] [Related]
20. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?
Giorgadze T; Rossi ED; Fadda G; Gupta PK; Livolsi VA; Baloch Z
Diagn Cytopathol; 2004 Nov; 31(5):307-12. PubMed ID: 15468114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
